StockData
CytoMed Therapeutics Ltd logo

CytoMed Therapeutics Ltd (GDTC) stock

GDTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 4/30
$0.78+0.01 (+1.18%)

Close on Nov 17, 2026Market cap $9.26MP/E –Yield –

CytoMed Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

CytoMed Therapeutics's price to sales ratio was 39.3× on Nov 11, 2026, against 395.8× a year earlier.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202639.3×−245.8
2025Dec 31, 2025285.0×–

More CytoMed Therapeutics figures

See a number that looks wrong?